Key result
Age ≥75 linked to ~2.1-fold higher risk of 48-hour NACE during cangrelor-supported PCI.
Why the study?
The clinical characteristics and in-hospital outcomes of elderly versus nonelderly patients treated with cangrelor during PCI were not well defined.
Does advanced age (≥75 years) increase the risk of net adverse clinical events in patients undergoing PCI treated with cangrelor?
Cohort (n=1,071)
Yes
Does advanced age (≥75 years) increase the risk of net adverse clinical events in patients undergoing PCI treated with cangrelor?
Elderly patients (aged ≥75 years) treated with cangrelor during PCI have a roughly twofold higher risk of early net adverse clinical events, driven by both ischemic and bleeding complications.
Answers are grounded in this paper and cite their sources.
May warrant closer monitoring in elderly PCI patients on cangrelor; leaves open whether age-specific regimens reduce risk.
BACKGROUND/OBJECTIVES: We aimed to assess the clinical characteristics and in-hospital outcomes of elderly vs. nonelderly patients treated with cangrelor during percutaneous coronary intervention (PCI). METHODS: Patients undergoing PCI with cangrelor between January 2019 and May 2023 in seven Italian institutions were retrospectively enrolled. Patients aged ≥75 years at the time of PCI were classified as elderly. The primary endpoint was net adverse clinical events (NACE), a composite of cardiovascular death, myocardial infarction, stroke, definite or probable stent thrombosis, and Bleeding Academic Research Consortium (BARC) types 2, 3, or 5 bleeding, evaluated at 48 h post-PCI. The impact of advanced age (≥75 years) on clinical outcomes was assessed using multivariable logistic regression (LR), inverse probability of treatment weighting (IPTW), and doubly robust (DR) models. RESULTS: A total of 1071 patients were included, of whom 340 (32%) were elderly. At 48 h, elderly patients had higher odds of NACE [odds ratio (OR) 2.11, 95% confidence interval (CI) 1.12-3.97, P = 0.021 by multivariable LR; OR 1.98, 95% CI 1.45-2.27, P < 0.001 with IPTW; and OR 2.09, 95% CI 1.51-2.93, P < 0.001 by DR estimation]. These results were driven by an increased risk of both ischemic and bleeding events, the latter including access-site and nonaccess-site hemorrhages of both minor and major severity. CONCLUSIONS: In this real-world study of patients undergoing PCI with cangrelor, elderly individuals accounted for one-third of the population. Elderly patients were at higher risk of NACE, driven by both ischemic and bleeding events.
No takes yet. Share an insight, caveat, or question.
Benenati et al. (2026) conducted a cohort in Patients undergoing percutaneous coronary intervention (n=1,071). Advanced age (≥75 years) vs. Nonelderly patients (<75 years) was evaluated on Net adverse clinical events (NACE), a composite of cardiovascular death, myocardial infarction, stroke, definite or probable stent thrombosis, and BARC types 2, 3, or 5 bleeding (OR 2.11, 95% CI 1.12-3.97, p=0.021). Advanced age (≥75 years) in patients undergoing PCI with cangrelor was associated with a higher risk of net adverse clinical events at 48 hours.
Synapse has enriched 10 related papers. Consider them for comparative context: